Related Experiment Videos
Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal
R E Reddingius1, C H Schröder, L A Monnens
1Department of Paediatrics, Sint Radboud University Hospital, Nijmegen, The Netherlands.
Insights
Recombinant human erythropoietin effectively treats renal anemia in children undergoing continuous ambulatory peritoneal dialysis (CAPD). Intraperitoneal administration improved hemoglobin and eliminated the need for transfusions without increasing peritonitis risk.
Area of Science:
- Pediatric Nephrology
- Hematology
Background:
- Renal anemia is a common complication in children treated with continuous ambulatory peritoneal dialysis (CAPD).
- Erythropoietin is a standard treatment for anemia, but its administration route in pediatric CAPD patients requires further investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of intraperitoneal administration of recombinant human erythropoietin (EPO) for treating renal anemia in children on CAPD.
Main Methods:
- A study involving 16 children on CAPD receiving intraperitoneal EPO.
- Treatment duration averaged 8.3 months, with hemoglobin levels and transfusion requirements monitored.
- Dosing started at 300 units/kg/week, adjusted based on patient response.
Main Results:
- Mean hemoglobin increased from 4.9 to 6.2 mmol/l within 6 months.
- Transfusion requirements decreased from 22 transfusions in the prior 6 months to zero after EPO initiation.
- No major adverse events or increased peritonitis incidence were reported.
Conclusions:
- Intraperitoneal EPO is an effective and safe treatment for renal anemia in pediatric CAPD patients.
- This administration route offers a viable alternative for managing anemia in this population.
Abstract:
In 16 children treated by continuous ambulatory peritoneal dialysis (CAPD) recombinant human erythropoietin was administered intraperitoneally for the treatment of renal anaemia. The mean treatment period was 8.3 months. Mean haemoglobin values increased from 4.9 mmol/l at start of therapy to 6.2 after 6 months. While 11 out of 16 children needed a total of 22 transfusions during the 6 months prior to therapy, no transfusions were needed after initiation of therapy. Patients started with a dose of 300 units/kg per week. After 6 months of therapy, the mean dose was 370 and after 12 months 279 units/kg per week. No major side-effects were observed. The incidence of peritonitis was not increased. We conclude that intraperitoneal administration of erythropoietin is effective in the treatment of renal anaemia in children treated by CAPD.